Respimat® Soft Mist(TM) Inhaler (SMI) is a novel, propellant-free device which produces a slow-moving, long-lasting aerosol that is easy to inhale and has excellent deposition efficiency. Satisfaction with and preference for Respimat® SMI was assessed in three randomised, open-label studies.
In study A (Canada; n=129; mean age 66.1), COPD patients received ipratropium bromide (IB; 20 or 40 ug) or placebo qid via Respimat® SMI for 6 months; in study B, (Germany; n=47; mean age 63.7) COPD patients received IB/fenoterol (10/25 or 20/50 ug) or placebo qid via Respimat® SMI for 12 weeks. In study C (Germany; n=245; mean age 55.3), COPD, asthma or mixed disease patients received, tid or qid, IB/fenoterol 20/50 ug via Respimat® SMI or 40/100 ug via pressurised metered dose inhaler (pMDI) for 7 weeks each in a crossover design. Questionnaires on device satisfaction, preference and willingness to continue were completed after each treatment period or at the end of the study.
Most patients in studies A and B (94 and 85%, respectively) said they would prefer to use Respimat® SMI over their current inhaler. Willingness to continue using Respimat® SMI was high (A, 80%; B, 72%), as was overall satisfaction with Respimat® SMI, with 74% (A) and 64% (B) giving ratings of 9 or 10 (10 = “extremely satisfied”). Of the 201 patients in study C who completed an assessment of both devices and expressed a preference, 162 (81%) preferred Respimat® SMI (p<0.001). Preference was unaffected by age or co-existing conditions that might adversely affect inhaler handling. Willingness-to-continue scores were significantly higher for Respimat® SMI than pMDI (p<0.001). Mean scores for 13 of the 15 items in the satisfaction questionnaire were higher for Respimat® SMI.
In these 3 studies, patients were highly satisfied with Respimat® SMI and the vast majority preferred this device to the pMDI.
Adherence to inhaler therapy and thus disease control may be enhanced when patients are offered an inhaler device that they prefer over the pMDI.
R.V. Hodder, None.